bullish
Eisai 1H FY18 (YE Mar'19) Results - First Glance
425 Views01 Nov 2018 16:45
Key highlights
Lenvima, Eisai’s key revenue driver, performed across regions (+43% to ¥14.3b in the US, +170% to ¥4.3b in Japan and +40% to ¥3.7b...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Eisai 1H FY18 (YE Mar'19) Results - First Glance01 Nov 2018
- BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns26 Jul 2018
- Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY1903 Jul 2018
- Eisai FY17 Earnings - First Glance17 May 2018
x